Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Progress-free Survival|Overall Response Rate|Adverse Events
Sponsor: Shanghai CP Guojian Pharmaceutical Co., Ltd.